Release Summary

NEUROVANCE ANNOUNCES AGREEMENT TO BE ACQUIRED BY OTSUKA PHARMACEUTICAL. The acquisition Will Support Late-Stage Development of Neurovance’s Investigational New Drug Centanafadine for ADHD.

Neurovance, Inc.